JP7234128B2 - シクロプロパンカルボン酸(5-{5-[n’-(2-クロロ-6-メチルベンゾイル)ヒドラジノカルボニル]-2-メチル-フェニルエチニル}-ピリジン-2イル)アミドの新規非晶質分散体 - Google Patents
シクロプロパンカルボン酸(5-{5-[n’-(2-クロロ-6-メチルベンゾイル)ヒドラジノカルボニル]-2-メチル-フェニルエチニル}-ピリジン-2イル)アミドの新規非晶質分散体 Download PDFInfo
- Publication number
- JP7234128B2 JP7234128B2 JP2019550640A JP2019550640A JP7234128B2 JP 7234128 B2 JP7234128 B2 JP 7234128B2 JP 2019550640 A JP2019550640 A JP 2019550640A JP 2019550640 A JP2019550640 A JP 2019550640A JP 7234128 B2 JP7234128 B2 JP 7234128B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- amorphous dispersion
- solid dosage
- polymeric carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
実施例Iの非晶質分散体の適切な量と、ビヒクルに懸濁した式Iの化合物の結晶形をイヌに経口投与した。様々な時間間隔で血液サンプルを採取し、式Iの化合物の血漿中濃度を記録した。血漿中のCmax、AUC0-t、及びAUC0-∞を下表に示す。
実施例Iの押出物の形態の非晶質分散体を、崩壊剤、吸上剤、界面活性剤、潤滑剤、緩衝剤、希釈剤等の他の従来の賦形剤と混合し、目標充填重量に対して適切なサイズの硬ゼラチンカプセルに充填した。充填したカプセルを、乾燥剤及び小児用安全クロージャを備えた適切な容量の高密度ポリエチレンボトルに詰めた。これらのカプセルを、40℃、相対湿度75%で6ヶ月間、加速安定条件に曝した。不純物及び関連物質は、保管前(初期)及び保管後に測定した。保管前及び40℃、相対湿度75%での6ヶ月間の保管後の両方の不純物レベルは、定量可能な限界を下回っていた。安定性研究データは、ステージIV不純物、アミン不純物、最大未知不純物、及び全不純物等の分解不純物が十分に許容範囲内であることを示した。このことは経口固体剤形の式Iの化合物の非晶質分散体が化学的に安定であることを実証した。
Claims (4)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201721005409 | 2017-03-15 | ||
IN201721005409 | 2017-03-15 | ||
PCT/IN2018/050147 WO2018167803A1 (en) | 2017-03-15 | 2018-03-15 | Novel amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[ n'-(2-chloro-6-methylbenzoyl) hydrazinocarbonyl] -2-methyl-phenylethynyl}-pyridin-2-yl) amide |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020510064A JP2020510064A (ja) | 2020-04-02 |
JP7234128B2 true JP7234128B2 (ja) | 2023-03-07 |
Family
ID=63521905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019550640A Active JP7234128B2 (ja) | 2017-03-15 | 2018-03-15 | シクロプロパンカルボン酸(5-{5-[n’-(2-クロロ-6-メチルベンゾイル)ヒドラジノカルボニル]-2-メチル-フェニルエチニル}-ピリジン-2イル)アミドの新規非晶質分散体 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11273126B2 (ja) |
EP (1) | EP3596049A4 (ja) |
JP (1) | JP7234128B2 (ja) |
CN (1) | CN110506036A (ja) |
AU (1) | AU2018235447B2 (ja) |
CA (1) | CA3056356A1 (ja) |
MA (1) | MA47798A (ja) |
RU (1) | RU2768887C2 (ja) |
WO (1) | WO2018167803A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010509289A (ja) | 2006-11-09 | 2010-03-25 | アボット ゲーエムベーハー ウント コンパニー カーゲー | チロシンキナーゼ阻害剤の経口投与用薬学的剤形 |
JP2015503613A (ja) | 2012-01-13 | 2015-02-02 | エックススプレイ マイクロパーティクルズ アクチエボラグXSpray Microparticles AB | 少なくとも1種のプロテインキナーゼ阻害剤及び少なくとも1種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
WO2015128298A1 (en) | 2014-02-27 | 2015-09-03 | Ratiopharm Gmbh | Pharmaceutical composition |
WO2016021707A1 (ja) | 2014-08-08 | 2016-02-11 | 中外製薬株式会社 | 4環性化合物の非晶質体 |
WO2016185490A1 (en) | 2015-05-18 | 2016-11-24 | Sun Pharma Advanced Research Company Limited | Novel amidoheteroaryl aroyl hydrazide ethynes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2495016T3 (da) * | 2005-12-23 | 2019-12-16 | Ariad Pharma Inc | Bicykliske heteroarylforbindelser |
US8461167B2 (en) * | 2006-05-08 | 2013-06-11 | Ariad Pharmaceuticals, Inc. | Acetylenic heteroaryl compounds |
JP2012516847A (ja) * | 2009-02-02 | 2012-07-26 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
RU2603833C2 (ru) * | 2010-11-08 | 2016-11-27 | Кадила Фармасьютикалз Лимитед | Фармацевтическая композиция таксоидов |
CA2825367C (en) * | 2011-01-21 | 2018-09-25 | Sun Pharma Advanced Research Company Ltd. | Diarylacetylene hydrazide containing tyrosine kinase inhibitors |
US8859541B2 (en) * | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
DK2861579T5 (da) * | 2012-05-15 | 2022-10-24 | Novartis Ag | Benzamidderivater til at hæmme aktiviteten af ABL1, ABL2 og BCR-ABL1 |
CN103664787B (zh) * | 2012-09-17 | 2015-09-09 | 南京圣和药业股份有限公司 | 炔杂芳环化合物及其应用 |
-
2018
- 2018-03-15 AU AU2018235447A patent/AU2018235447B2/en active Active
- 2018-03-15 CA CA3056356A patent/CA3056356A1/en not_active Abandoned
- 2018-03-15 RU RU2019132074A patent/RU2768887C2/ru active
- 2018-03-15 JP JP2019550640A patent/JP7234128B2/ja active Active
- 2018-03-15 WO PCT/IN2018/050147 patent/WO2018167803A1/en unknown
- 2018-03-15 US US16/494,598 patent/US11273126B2/en active Active
- 2018-03-15 MA MA047798A patent/MA47798A/fr unknown
- 2018-03-15 EP EP18768528.4A patent/EP3596049A4/en not_active Withdrawn
- 2018-03-15 CN CN201880018613.4A patent/CN110506036A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010509289A (ja) | 2006-11-09 | 2010-03-25 | アボット ゲーエムベーハー ウント コンパニー カーゲー | チロシンキナーゼ阻害剤の経口投与用薬学的剤形 |
JP2015503613A (ja) | 2012-01-13 | 2015-02-02 | エックススプレイ マイクロパーティクルズ アクチエボラグXSpray Microparticles AB | 少なくとも1種のプロテインキナーゼ阻害剤及び少なくとも1種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
WO2015128298A1 (en) | 2014-02-27 | 2015-09-03 | Ratiopharm Gmbh | Pharmaceutical composition |
WO2016021707A1 (ja) | 2014-08-08 | 2016-02-11 | 中外製薬株式会社 | 4環性化合物の非晶質体 |
WO2016185490A1 (en) | 2015-05-18 | 2016-11-24 | Sun Pharma Advanced Research Company Limited | Novel amidoheteroaryl aroyl hydrazide ethynes |
Non-Patent Citations (3)
Title |
---|
Drug Delivery Technology,2010年,Vol. 10, No. 3,pp. 20, 22-27 |
European Journal of Pharmaceutical Sciences,2012年,Vol. 45,pp. 336-343 |
Journal of Controlled Release,2016年,Vol. 239,pp. 118-127 |
Also Published As
Publication number | Publication date |
---|---|
AU2018235447A1 (en) | 2019-10-03 |
EP3596049A4 (en) | 2021-01-13 |
RU2019132074A3 (ja) | 2021-07-13 |
CN110506036A (zh) | 2019-11-26 |
CA3056356A1 (en) | 2018-09-20 |
MA47798A (fr) | 2020-01-22 |
JP2020510064A (ja) | 2020-04-02 |
EP3596049A1 (en) | 2020-01-22 |
WO2018167803A9 (en) | 2019-02-28 |
US20210113470A1 (en) | 2021-04-22 |
US11273126B2 (en) | 2022-03-15 |
WO2018167803A1 (en) | 2018-09-20 |
AU2018235447B2 (en) | 2021-12-09 |
RU2768887C2 (ru) | 2022-03-25 |
RU2019132074A (ru) | 2021-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023027309A (ja) | 4-メチル-3-キノリン-3-イルエチニル-安息香酸n’-(2-クロロ-6-メチル-ベンゾイル)ヒドラジドの新規非晶質分散体 | |
JP4875001B2 (ja) | アリピプラゾールの湿式造粒医薬組成物 | |
ES2526415T3 (es) | Comprimidos farmacéuticos de aripiprazol cristalino de tipo II | |
US10507204B2 (en) | Pharmaceutical composition comprising amorphous lenalidomide | |
WO2015124995A1 (en) | Solid dosage forms of rivaroxaban | |
JP2020532559A (ja) | 経口投与可能なhifプロリルヒドロキシラーゼ阻害剤の共結晶 | |
WO2018199282A1 (ja) | エンザルタミドを含有する経口投与用医薬組成物 | |
BR112012002069B1 (pt) | processo para a fabricação de um granulado contendo ezetimibe microcristalino | |
EA017553B1 (ru) | Гидробромид ивабрадина | |
JP7234128B2 (ja) | シクロプロパンカルボン酸(5-{5-[n’-(2-クロロ-6-メチルベンゾイル)ヒドラジノカルボニル]-2-メチル-フェニルエチニル}-ピリジン-2イル)アミドの新規非晶質分散体 | |
WO2021243186A1 (en) | Pralsetinib pharmaceutical compositions | |
RU2777569C2 (ru) | Новая аморфная дисперсия n'-(2-хлор-6-метил- бензоил)гидразида 4-метил-3-хинолин-3-илэтинил-бензойной кислоты | |
EP3095443A1 (en) | Pharmaceutical composition comprising deferasirox | |
WO2017141271A1 (en) | Stable pharmaceutical composition of afatinib | |
JPWO2015199115A1 (ja) | 経口投与用医薬組成物 | |
JP6832706B2 (ja) | 固形医薬組成物 | |
Mohammed et al. | Solid dispersion: application and limitations | |
RU2673228C2 (ru) | Фармацевтическая композиция, включающая твердую дисперсию тадалафила | |
JP2022102543A (ja) | オセルタミビルを含む錠剤及びその製造方法 | |
WO2019138424A1 (en) | Stable pharmaceutical compositions comprising lenalidomide | |
GR20150100471A (el) | Φαρμακευτικο σκευασμα περιεχον απρεπιταντη και μεθοδος παρασκευης αυτου |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210310 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20211025 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20211105 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220111 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220407 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221221 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221221 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230104 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230124 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230222 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7234128 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |